MX2014007642A - Tratamiento del deterioro cognitivo del sindrome de hunter mediante suministro intratecal de iduronato-2-sulfatasa. - Google Patents
Tratamiento del deterioro cognitivo del sindrome de hunter mediante suministro intratecal de iduronato-2-sulfatasa.Info
- Publication number
- MX2014007642A MX2014007642A MX2014007642A MX2014007642A MX2014007642A MX 2014007642 A MX2014007642 A MX 2014007642A MX 2014007642 A MX2014007642 A MX 2014007642A MX 2014007642 A MX2014007642 A MX 2014007642A MX 2014007642 A MX2014007642 A MX 2014007642A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- sulfatase
- cognitive impairment
- iduronate
- hunter syndrome
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención proporciona un método para tratar el deterioro cognitivo del síndrome de Hunter; entre otras cosas, la presente invención proporciona un método que comprende una etapa de administrar intratecalmente a un sujeto que necesita el tratamiento, una enzima de iduronato-2-sulfatasa (12S) recombinante a una dosis terapéuticamente efectiva y a un intervalo de administración por un período de tratamiento suficiente para mejorar, estabilizar o reducir la disminución de una o más funciones cognitivas, adaptativas, motoras y/o ejecutivas, en relacion con un control.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161580027P | 2011-12-23 | 2011-12-23 | |
US201261590804P | 2012-01-25 | 2012-01-25 | |
US201261590797P | 2012-01-25 | 2012-01-25 | |
US201261609173P | 2012-03-09 | 2012-03-09 | |
US201261734365P | 2012-12-06 | 2012-12-06 | |
PCT/US2012/071495 WO2013096912A2 (en) | 2011-12-23 | 2012-12-21 | Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014007642A true MX2014007642A (es) | 2015-03-19 |
MX367395B MX367395B (es) | 2019-08-20 |
Family
ID=48669720
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014007642A MX367395B (es) | 2011-12-23 | 2012-12-21 | Iduronato-2-sulfatasa para usarse en el tratamiento del deterioro cognitivo del síndrome de hunter mediante suministro intratecal. |
MX2019009846A MX2019009846A (es) | 2011-12-23 | 2014-06-20 | Iduronato-2-sulfatasa para usarse en el tratamiento del deterioro cognitivo del sindrome de hunter mediante suministro intratecal. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019009846A MX2019009846A (es) | 2011-12-23 | 2014-06-20 | Iduronato-2-sulfatasa para usarse en el tratamiento del deterioro cognitivo del sindrome de hunter mediante suministro intratecal. |
Country Status (9)
Country | Link |
---|---|
US (3) | US9682129B2 (es) |
EP (1) | EP2793933B1 (es) |
AU (1) | AU2012358223B2 (es) |
BR (1) | BR112014015352A8 (es) |
CA (1) | CA2859988A1 (es) |
EA (1) | EA201792099A1 (es) |
ES (1) | ES2728447T3 (es) |
MX (2) | MX367395B (es) |
WO (1) | WO2013096912A2 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201792099A1 (ru) * | 2011-12-23 | 2018-05-31 | Шир Хьюман Дженетик Терапис, Инк. | Лечение когнитивных нарушений при синдроме хантера путем интратекальной доставки идуронат-2-сульфатазы |
KR20170004814A (ko) | 2015-07-02 | 2017-01-11 | 주식회사 녹십자 | 헌터증후군 치료제 |
KR20180090387A (ko) | 2015-12-30 | 2018-08-10 | 주식회사 녹십자 | 헌터증후군을 치료하기 위한 방법 및 조성물 |
MA50746A (fr) | 2017-10-02 | 2020-08-12 | Denali Therapeutics Inc | Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6217552B1 (en) | 1999-03-01 | 2001-04-17 | Coaxia, Inc. | Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma |
US6537785B1 (en) | 1999-09-14 | 2003-03-25 | Genzyme Glycobiology Research Institute, Inc. | Methods of treating lysosomal storage diseases |
AU2003302724A1 (en) * | 2002-08-13 | 2004-07-09 | Mcivor, Scott, R. | Methods of using vectors to treat metabolic disorders |
US7442372B2 (en) * | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
AR059089A1 (es) * | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
US7722865B2 (en) * | 2008-01-18 | 2010-05-25 | Biomarin Pharmaceutical Inc. | Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof |
IL291554B2 (en) * | 2010-06-25 | 2024-02-01 | Shire Human Genetic Therapies | Administering therapeutic agents to the central nervous system |
PL2588130T3 (pl) * | 2010-06-25 | 2017-09-29 | Shire Human Genetic Therapies, Inc. | Dostarczanie środków terapeutycznych do OUN |
RU2012154576A (ru) | 2010-06-25 | 2014-07-27 | Шир Хьюман Дженетик Терапис, Инк. | Способы и композиции для доставки к цнс гепаран-n-сульфатазы |
JP6045492B2 (ja) | 2010-06-25 | 2016-12-14 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | イズロン酸−2−スルファターゼのcns送達のための方法および組成物 |
EA201792099A1 (ru) | 2011-12-23 | 2018-05-31 | Шир Хьюман Дженетик Терапис, Инк. | Лечение когнитивных нарушений при синдроме хантера путем интратекальной доставки идуронат-2-сульфатазы |
-
2012
- 2012-12-21 EA EA201792099A patent/EA201792099A1/ru unknown
- 2012-12-21 BR BR112014015352A patent/BR112014015352A8/pt not_active Application Discontinuation
- 2012-12-21 AU AU2012358223A patent/AU2012358223B2/en active Active
- 2012-12-21 EP EP12860231.5A patent/EP2793933B1/en active Active
- 2012-12-21 ES ES12860231T patent/ES2728447T3/es active Active
- 2012-12-21 MX MX2014007642A patent/MX367395B/es active IP Right Grant
- 2012-12-21 WO PCT/US2012/071495 patent/WO2013096912A2/en active Application Filing
- 2012-12-21 US US14/367,864 patent/US9682129B2/en active Active
- 2012-12-21 CA CA2859988A patent/CA2859988A1/en not_active Abandoned
-
2014
- 2014-06-20 MX MX2019009846A patent/MX2019009846A/es unknown
-
2017
- 2017-05-03 US US15/585,927 patent/US10568941B2/en active Active
-
2020
- 2020-01-15 US US16/744,140 patent/US11357832B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2793933A4 (en) | 2016-06-08 |
US20180071371A1 (en) | 2018-03-15 |
EP2793933A2 (en) | 2014-10-29 |
US10568941B2 (en) | 2020-02-25 |
WO2013096912A3 (en) | 2015-06-18 |
AU2012358223A1 (en) | 2014-07-03 |
WO2013096912A2 (en) | 2013-06-27 |
EP2793933B1 (en) | 2019-04-17 |
US9682129B2 (en) | 2017-06-20 |
AU2012358223B2 (en) | 2018-01-18 |
MX367395B (es) | 2019-08-20 |
BR112014015352A2 (pt) | 2017-06-13 |
ES2728447T3 (es) | 2019-10-24 |
US20200376093A1 (en) | 2020-12-03 |
US20150328289A1 (en) | 2015-11-19 |
US11357832B2 (en) | 2022-06-14 |
MX2019009846A (es) | 2019-10-14 |
BR112014015352A8 (pt) | 2017-06-13 |
EA201792099A1 (ru) | 2018-05-31 |
CA2859988A1 (en) | 2013-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201590880A1 (ru) | Композиции и способы лечения протеинопатий | |
AU2018253546A1 (en) | Aromatic-cationic peptides and methods for using same | |
GB2491327A (en) | Delayed prolonged drug delivery | |
AU2012284088A8 (en) | Heterocyclic compounds and uses thereof | |
WO2012145651A3 (en) | Compounds for the treatment of neuropsychiatric disorders | |
MX370567B (es) | Tratamiento de mielosupresion. | |
GB2491328A (en) | Immediate/delayed drug delivery | |
MX366175B (es) | Composiciones fosfolipidicas terapeuticas concentradas. | |
PH12014501491A1 (en) | Subcutaneous therapeutic use of dpp-4 inhibitor | |
BR112012033738A2 (pt) | método para o tratamento de transtorno bipolar | |
MX2014011836A (es) | Administracion subcutanea de iduronato-2-sulfatasa. | |
MX2019009846A (es) | Iduronato-2-sulfatasa para usarse en el tratamiento del deterioro cognitivo del sindrome de hunter mediante suministro intratecal. | |
CA2881554C (en) | Methods for inhibiting fascin | |
DK2714888T3 (da) | Rekombinant gær | |
IN2014DN08199A (es) | ||
EP2490700A4 (en) | EXTERNAL SKIN CARE COMPOSITION COMPRISING SALT AND SUGAR AS ACTIVE INGREDIENTS FOR PREVENTING AND TREATING VAGINOSIS AND USE THEREOF | |
NZ596780A (en) | Immunoregulatory peptides and methods of use | |
MX2021001394A (es) | Metodo para mejorar la eficacia de un agente anticanceroso. | |
MX2016006256A (es) | Tratamiento de glaucoma usando laquinimod. | |
EA201491047A1 (ru) | Лечение когнитивных нарушений при синдроме хантера путем интратекальной доставки идуронат-2-сульфатазы | |
MX358512B (es) | Uso de (r)-7cloro-n-(quinuclidin-3-il) benzo[b] tiofeno-2-carboxamida o una sal farmacéuticamente aceptable de la misma para preparar una composición farmacéutica en el tratamiento de una disfunción cognitiva. | |
WO2012158776A3 (en) | Combination therapy for treatment of cancer | |
MX2014000870A (es) | Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina. | |
MX359171B (es) | Tratamiento para diabetes tipo i y tipo ii. | |
EP2692351A4 (en) | ACTIVE FRACTION OF PAULLINIA CUPANA WITH IMPROVED EFFICACY AGAINST TEMPTATION, PROCESS FOR PREPARING AN ACTIVE FRACTION, USE THEREOF, PHARMACEUTICAL COMPOSITION, MEDICAMENTS AND TREATMENT FOR TREATMENT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HH | Correction or change in general | ||
FG | Grant or registration |